東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Can biopatents survive as a matter o...

Echevarria, Rebeca.

FindBook

Google Book

Amazon

博客來

Can biopatents survive as a matter of public policy?

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Can biopatents survive as a matter of public policy?/
作者:	Echevarria, Rebeca.
面頁冊數:	71 p.
附註:	Source: Masters Abstracts International, Volume: 53-06.
Contained By:	Masters Abstracts International53-06(E).
標題:	Ethics. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1566179
ISBN:	9781321233155

Can biopatents survive as a matter of public policy?
Echevarria, Rebeca.

Can biopatents survive as a matter of public policy? - 71 p.

Source: Masters Abstracts International, Volume: 53-06.

Thesis (M.A.)--Wake Forest University, 2014.

This item must not be sold to any third party vendors.

Bioproduct patents hold great promise for developing new and impactful medical treatments, but much of their potential depends on the ability of federal patent regulations to foster innovation and progress, both in their regulatory effect and through predictable and consistent application of patent law. Unfortunately, patent law is failing in both respects. Recent studies show that patents do not ultimately foster innovation and progress, especially in the biotechnology sector. Recent Supreme Court decisions, Mayo v. Prometheus and Association for Molecular Pathology v. Myriad. have also raised uncertainty as to the patent eligibility of stem cells. This uncertainty can ultimately block pathways to market and dampen investor interest in commercialization, slowing the overall development of new technical applications and reducing public benefit.

ISBN: 9781321233155Subjects--Topical Terms:

517264
Ethics.

Can biopatents survive as a matter of public policy?
LDR:02790nmm a2200325 4500 001 2060849
005 20150918092323.5
008 170521s2014 ||||||||||||||||| ||eng d
020 $a 9781321233155
035 $a (MiAaPQ)AAI1566179
035 $a AAI1566179
040 $a MiAaPQ $c MiAaPQ
100 1 $a Echevarria, Rebeca. $3 3175042
245 1 0 $a Can biopatents survive as a matter of public policy?
300 $a 71 p.
500 $a Source: Masters Abstracts International, Volume: 53-06.
500 $a Advisers: Mark Hall; Christine N. Coughlin.
502 $a Thesis (M.A.)--Wake Forest University, 2014.
506 $a This item must not be sold to any third party vendors.
520 $a Bioproduct patents hold great promise for developing new and impactful medical treatments, but much of their potential depends on the ability of federal patent regulations to foster innovation and progress, both in their regulatory effect and through predictable and consistent application of patent law. Unfortunately, patent law is failing in both respects. Recent studies show that patents do not ultimately foster innovation and progress, especially in the biotechnology sector. Recent Supreme Court decisions, Mayo v. Prometheus and Association for Molecular Pathology v. Myriad. have also raised uncertainty as to the patent eligibility of stem cells. This uncertainty can ultimately block pathways to market and dampen investor interest in commercialization, slowing the overall development of new technical applications and reducing public benefit.
520 $a The Supreme Court has ruled on patent eligibility of several biopatents, but the future of stem cell patents is yet to be determined. Stem cells hold great promise for medical cures and treatments, and if stem cell research is inhibited, the public will suffer. Therefore, this thesis will explore the patent-eligibility of two types of stem cells: human embryonic stem cells and induced pluripotent stem cells as a basis for the argument that biopatents cannot survive current patent law as a matter of public policy. After explaining how various types of stem cells are isolated and cultured, discussing what subject matter is patent-eligible, and analyzing the legal trend in bioproduct patents, this thesis posits that stem cell patents, like other biopatents, ultimately do more harm to society than the benefits they purport to provide and concludes that patent law needs to be industry specific if stem cell and other bioproduct research are to thrive.
590 $a School code: 0248.
650 4 $a Ethics. $3 517264
650 4 $a Biomedical engineering. $3 535387
650 4 $a Patent law. $3 3168356
650 4 $a Medical ethics. $3 526828
690 $a 0394
690 $a 0541
690 $a 0562
690 $a 0497
710 2 $a Wake Forest University. $b Bioethics. $3 2095518
773 0 $t Masters Abstracts International $g 53-06(E).
790 $a 0248
791 $a M.A.
792 $a 2014
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=1566179